Gujarathi Rushabh, Franses Joseph W, Pillai Anjana, Liao Chih-Yi
Section of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, IL, United States.
Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, University of Chicago, Chicago, IL, United States.
Front Oncol. 2024 Aug 29;14:1432423. doi: 10.3389/fonc.2024.1432423. eCollection 2024.
Targeted therapies are the mainstay of systemic therapies for patients with advanced, unresectable, or metastatic hepatocellular carcinoma. Several therapeutic targets, such as c-Met, TGF-β, and FGFR, have been evaluated in the past, though results from these clinical studies failed to show clinical benefit. However, these remain important targets for the future with novel targeted agents and strategies. The Wnt/β-catenin signaling pathway, c-Myc oncogene, GPC3, PPT1 are exciting novel targets, among others, currently undergoing evaluation. Through this review, we aim to provide an overview of previously evaluated and potentially novel therapeutic targets and explore their continued relevance in ongoing and future studies for HCC.
靶向治疗是晚期、不可切除或转移性肝细胞癌患者全身治疗的主要手段。过去已经对几个治疗靶点进行了评估，如c-Met、转化生长因子-β（TGF-β）和成纤维细胞生长因子受体（FGFR），尽管这些临床研究的结果未能显示出临床获益。然而，随着新型靶向药物和策略的出现，这些靶点在未来仍然很重要。Wnt/β-连环蛋白信号通路、c-Myc癌基因、磷脂酰肌醇蛋白聚糖3（GPC3）、PPT1等都是目前正在评估的令人兴奋的新型靶点。通过这篇综述，我们旨在概述先前评估过的以及潜在的新型治疗靶点，并探讨它们在肝细胞癌正在进行的和未来的研究中的持续相关性。
